Patents by Inventor Gerhard Nehmiz

Gerhard Nehmiz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION
    Publication number: 20150147295
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 28, 2015
    Inventors: Wulf Otto BOECHER, Gerhard NEHMIZ, Wiebke SAUTER, Gerhard G. STEINMANN, Heike ZIMDAHL-GELLING
  • COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE SUB-POPULATION
    Publication number: 20140271544
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in patients having genetic variations located near the IL28B gene, including SNP rs12979860 with a non-CC genotype and SNP rs8099917 with a non-TT genotype.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 18, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Wulf Otto BOECHER, Gerhard NEHMIZ, Wiebke SAUTER, Gerhard G. STEINMANN, Heike ZIMDAHL-GELLING
  • ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS
    Publication number: 20130288957
    Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that has genetic variations located near the IL28B gene, including SNP rs12979860 with a CC or non-CC genotype and SNP rs8099917 with a TT or non-TT genotype.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Federico MENSA, Gerhard NEHMIZ
  • Potent inhibitor of HCV serine protease
    Publication number: 20040138109
    Abstract: Disclosed are oral pharmaceutical compositions, kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein the following Compound (1), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range: 1
    Type: Application
    Filed: September 16, 2003
    Publication date: July 15, 2004
    Applicants: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & CO. KG
    Inventors: Shirlynn Chen, Jens Oliver Croenlein, Gerhard Nehmiz, Gerhard Steinmann, Jocelyn Abella Gunn, Phuong Do Costa